Duke-NUS Skin Barrier Breakthrough: MFSD2A Lipid Transporter Revealed in PNAS Study

Duke-NUS Researchers Unveil MFSD2A's Critical Role in Skin Barrier Function

In a groundbreaking discovery, scientists at Duke-NUS Medical School in Singapore have identified the protein MFSD2A, or Major Facilitator Superfamily Domain Containing 2A, as a key lipid transporter essential for maintaining the skin's protective barrier. Published in the prestigious Proceedings of the National Academy of Sciences (PNAS), the study reveals how MFSD2A shuttles lysophosphatidylcholine (LPC) lipids from the bloodstream directly into skin keratinocytes, the primary cells of the epidermis. This process ensures the skin remains impermeable to pathogens, allergens, and excessive water loss, a function often compromised in common conditions like atopic dermatitis and psoriasis.

The epidermis, the outermost layer of skin, relies on a complex lipid matrix to form its waterproof seal. Keratinocytes differentiate from the basal layer upward, culminating in the stratum corneum, a brick-and-mortar structure where corneocytes (dead keratinocytes) are embedded in lipid lamellae. These lipids, including acylceramides rich in linoleic acid, are packaged in lamellar bodies and secreted to fortify the barrier. Disruptions lead to chronic inflammation and heightened disease risk, affecting millions worldwide, including a significant portion of Singaporeans.

The Science Behind the Skin Barrier

The skin barrier's integrity hinges on precise lipid composition. Linoleic acid, an essential polyunsaturated fatty acid (PUFA), is pivotal for acylceramide production, esterified to omega-hydroxylated very long-chain ceramides by enzymes like CYP4F22 and PNPLA1. Deficiencies in these pathways cause rare genetic disorders such as autosomal recessive congenital ichthyosis, characterized by severe scaling and barrier failure.

Daily epidermal turnover—every 8-10 days in mice, slightly longer in humans—demands constant lipid replenishment. Plasma LPCs, particularly LPC-18:2 (linoleoyl species), serve as carriers of linoleic acid. Without efficient uptake, keratinocytes struggle to synthesize phospholipids and triglycerides (TAGs), precursors for barrier lipids. Duke-NUS's work demonstrates MFSD2A's indispensable role here, extending its known function beyond the blood-brain barrier (BBB).

From Brain to Skin: MFSD2A's Expanding Portfolio

Prof. David L. Silver's lab at Duke-NUS first identified MFSD2A in 2014 as the BBB transporter for docosahexaenoic acid (DHA)-enriched LPC, crucial for brain development. Mutations cause microcephaly syndrome, underscoring its importance. Subsequent studies revealed MFSD2A's expression in other tissues like retina, lung, and now epidermis. In skin, single-cell RNA sequencing and lineage tracing confirmed MFSD2A in suprabasal keratinocytes, aligning with lamellar body secretion sites.

This multifunctionality highlights LPCs' versatility as lipid donors, adapting to tissue-specific needs. In skin, LPC-18:2 predominates over LPC-DHA, prioritizing barrier fortification over neural signaling.

Unpacking the Study: Innovative Methods and Revelatory Results

The PNAS paper employed sophisticated mouse models: epidermis-specific inducible knockout (2aEpKO) using Krt5-CreERT2, alongside whole-body knockouts. Tamoxifen induction triggered barrier defects within weeks—redness, scaling, hyperplasia, and parakeratosis (retained nuclei in stratum corneum).

• Histology showed thickened epidermis, disrupted desquamation, and retained lamellar bodies/mitochondria via electron microscopy.
• RNA-seq revealed upregulated proliferation markers (Krt6) and downregulated cornified envelope genes (FLG, LOR).
• Lipidomics via shotgun mass spectrometry exposed reduced phosphatidylcholine (PC)-18:2 (15% drop) and TAG-18:2 (79% drop), mimicking essential fatty acid deficiency.

In vitro, MFSD2A-deficient keratinocytes failed stratification in organotypic cultures. Human primary keratinocytes mirrored this: MFSD2A knockdown via siRNA slashed LPC uptake (LightOx-LPC assay) and differentiation markers (KRT1/10, FLG) upon LPC-18:1/18:2 supplementation.

Mouse Models Mimic Human Skin Disorders

2aEpKO mice exhibited spontaneous dermatitis, with heterozygous showing milder traits, suggesting dose-dependency. Transmission electron microscopy captured immature lamellar bodies and persistent organelles in corneocytes, hallmarks of barrier dysfunction. These phenotypes parallel atopic dermatitis, where filaggrin mutations impair lipid processing.Read the full PNAS study.

While human MFSD2A mutations primarily affect brain, reduced epidermal expression in eczema/psoriasis biopsies hints at contributory roles.

Implications for Singapore's Dermatology Landscape

Singapore's tropical climate exacerbates skin barrier issues. Approximately 10% of adults have atopic dermatitis, with rising pediatric cases amid urbanization and pollution. Psoriasis affects 1-2%, straining healthcare. MFSD2A insights could inspire LPC-18:2 supplements or topical therapies, aligning with Singapore's precision medicine push via the National Precision Medicine program.

Duke-NUS, a cornerstone of Singapore's biomedical ecosystem, exemplifies A*STAR and SingHealth collaborations fostering translational research.

Spotlight on Duke-NUS: Singapore's Research Powerhouse

Duke-NUS Medical School, established in 2005 as a Duke University-NUS partnership, integrates PhD training with clinical practice. Housing Silver's Cardiovascular & Metabolic Disorders Programme, it secures NMRC grants exceeding S$100 million annually. Alumni lead global trials, and facilities like advanced lipidomics labs enable breakthroughs like this.Duke-NUS press release.

This PNAS publication elevates Singapore's research profile, attracting talent amid Biopolis expansion.

Prof. David Silver and the Trailblazing Team

Prof. Silver, Programme Co-Lead, pioneered MFSD2A research, authoring over 50 papers. Senior Research Fellow Bernice H. Wong and Dwight L.A. Galam co-led, leveraging expertise in lipidomics and mouse genetics. Their interdisciplinary approach—spanning bioinformatics, imaging, and functional assays—exemplifies Duke-NUS training.

Therapeutic Horizons: Boosting LPC Transport

Future avenues include MFSD2A agonists or LPC-18:2 formulations for barrier repair. Preclinical tests could validate efficacy in AD models. Singapore's dermatology clinics, like NUH and SGH, may pioneer trials, reducing reliance on steroids/immunosuppressants.

• Potential for dietary interventions rich in linoleate precursors.
• Gene therapy for rare ichthyoses.
• Personalized skincare via lipid profiling.

Cultivating Research Talent in Singapore

Duke-NUS's MD-PhD tracks and postdoc programs nurture experts. With 1,000+ researchers, it offers roles in lipid biology, dermatology, and biotech startups. Singapore's Research, Innovation & Enterprise 2025 plan invests S$25 billion, creating jobs at A*STAR, NUS, NTU.

For aspiring academics, explore faculty positions or adjunct roles bridging clinic and lab.

Photo by DIEGO SÁNCHEZ on Unsplash

Global Echoes and Singapore's Leadership

This work resonates amid rising skin disease burdens from climate change. Singapore positions as Asia's dermato-research hub, collaborating with Japan and Australia on lipid metabolism. Outlook: Enhanced barrier therapies by 2030, reducing economic costs (S$500M+ annually).